Delayed contrast-enhanced computed tomography for assessment of myocardial injury after coronavirus disease 2019 (COVID-19) infectio
Not Applicable
Recruiting
- Conditions
- coronavirus disease 2019 (COVID-19) infection
- Registration Number
- JPRN-UMIN000044762
- Lead Sponsor
- Hokkaido Cardiovascular Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 400
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients expected to live a year or less 2. Patients with insufficient image quality of delayed contrast-enhanced computed tomography 3. Patients who withdraw their consent 4. Patients who contact persons judge as ineligible for this study
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Major adverse cardiovascular events (MACE: the composite of all-cause mortality, lethal ventricular arrhythmias [sustained ventricular tachycardia/ventricular fibrillation], myocardial infarction, and stroke), heart failure or unstable angina requiring hospitalization, and thromboembolic events after the delayed contrast-enhanced computed tomography examination.
- Secondary Outcome Measures
Name Time Method The prespecified secondary outcomes of the study are as follows: 1. prevalence of coronary artery disease and myocardial injury assessed by contrast-enhanced computed tomography. 2. diagnostic value of delayed contrast-enhanced computed tomography for the assessment of myocardial injury in comparison with late gadolinium enhancement cardiovascular magnetic resonance 3. cross-sectional and longitudinal associations between myocardial injury, echocardiographic indices, and biomarkers. 4. incidence and predictors of all-cause death, MACE, MACE+.